Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nielsen, S.
Right arrow Articles by Jørgensen, J. O.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nielsen, S.
Right arrow Articles by Jørgensen, J. O.L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:2301-2308, 2001
© 2001 by the American Diabetes Association, Inc.

Pharmacological Antilipolysis Restores Insulin Sensitivity During Growth Hormone Exposure

Steen Nielsen, Niels Møller, Jens S. Christiansen, and Jens O.L. Jørgensen

Medical Department M, Aarhus University Hospital, DK-8000 Aarhus C, Denmark

Stimulation of lipolysis and the induction of resistance to insulin’s actions on glucose metabolism are well-recognized effects of growth hormone (GH). To evaluate whether these two features are causally linked, we studied the impact of pharmacologically induced antilipolysis in seven GH-deficient patients (mean [± SE] age 37 ± 4 years). Each subject was studied under four different conditions: during continuation of GH replacement alone (A), after discontinuation of GH replacement for 2 days (B), after GH replacement and short-term coadministration of acipimox (250 mg, p.o., b.i.d., for 2 days) (C), and after administration of acipimox alone (D). At the end of each study, total and regional substrate metabolisms were assessed in the basal state and after a 3-h hyperinsulinemic/euglycemic clamp. Serum levels of free fatty acids (FFAs) were elevated with GH alone (A) and suppressed with acipimox (C and D). Basal rates of lipid oxidation were highest with GH alone (A), and suppressed by 50% with acipimox (B versus D, P < 0.01; A versus C, P < 0.05). Basal glucose oxidation rates were lowest with GH alone (A) and highest with acipimox (C and D) (P = 0.01). Insulin-stimulated rates of total glucose turnover were significantly lower with GH alone as compared with all other conditions (P = 0.004). Insulin sensitivity as assessed by the M value (rate of glucose infusion) was reduced with GH alone as compared with all other conditions (M value in mg · kg-1 · min-1: GH alone [A], 2.55 ± 0.64; discontinuation of GH [B], 4.01 ± 0.70; GH plus acipimox [C], 3.96 ± 1.34; acipimox alone [D], 4.96 ± 0.91; P < 0.01). During pharmacological antilipolysis, GH did not significantly influence insulin sensitivity (C versus D; P = 0.19). From our results, we reached the following conclusions: 1) Our data strongly suggest that the insulin antagonistic actions of GH on glucose metabolism are causally linked to the concomitant activation of lipolysis. 2) In addition, GH may induce residual insulin resistance through non–FFA-dependent mechanisms. 3) The cellular and molecular mechanisms subserving the insulin antagonistic effects of GH remain to be elucidated.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. Lindberg-Larsen, N. Moller, O. Schmitz, S. Nielsen, M. Andersen, H. Orskov, and J. O. L. Jorgensen
The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1724 - 1728.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. C. Gormsen, N. Jessen, J. Gjedsted, S. Gjedde, H. Norrelund, S. Lund, J. S. Christiansen, S. Nielsen, O. Schmitz, and N. Moller
Dose-Response Effects of Free Fatty Acids on Glucose and Lipid Metabolism during Somatostatin Blockade of Growth Hormone and Insulin in Humans
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1834 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. B. Krag, L. C. Gormsen, Z. Guo, J. S. Christiansen, M. D. Jensen, S. Nielsen, and J. O. L. Jorgensen
Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E920 - E927.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. O. L. Jorgensen, N. Jessen, S. B. Pedersen, E. Vestergaard, L. Gormsen, S. A. Lund, and N. Billestrup
GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E899 - E905.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
E T Vestergaard, T K Hansen, S Nielsen, N Moller, J S Christiansen, and J O L Jorgensen
Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis
Eur. J. Endocrinol., October 1, 2005; 153(4): 545 - 549.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Svensson, H. Herlitz, P.-A. Lundberg, and G. Johannsson
Adiponectin, Leptin, and Erythrocyte Sodium/Lithium Countertransport Activity, But Not Resistin, Are Related to Glucose Metabolism in Growth Hormone-Deficient Adults
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2290 - 2296.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Jessen, C. B. Djurhuus, J. O. L. Jorgensen, L. S. Jensen, N. Moller, S. Lund, and O. Schmitz
Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E194 - E199.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Ameen, D. Linden, B.-M. Larsson, A. Mode, A. Holmang, and J. Oscarsson
Effects of gender and GH secretory pattern on sterol regulatory element-binding protein-1c and its target genes in rat liver
Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1039 - E1048.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Norrelund, C. Djurhuus, J. O. L. Jorgensen, S. Nielsen, K. S. Nair, O. Schmitz, J. S. Christiansen, and N. Moller
Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E737 - E743.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. U. Freda, C. M. Reyes, I. M. Conwell, R. E. Sundeen, and S. L. Wardlaw
Serum Ghrelin Levels in Acromegaly: Effects of Surgical and Long-Acting Octreotide Therapy
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2037 - 2044.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Svensson and B.-A. Bengtsson
Growth Hormone Replacement Therapy and Insulin Sensitivity
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1453 - 1454.
[Full Text] [PDF]

Home page
 Br. J. Sports. Med.Home page
M J Rennie
Claims for the anabolic effects of growth hormone: a case of the Emperor's new clothes?
Br. J. Sports Med., April 1, 2003; 37(2): 100 - 105.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.